HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief

This article was originally published in The Rose Sheet

Executive Summary

ICCR’s new centralized website provides access to documents on topics of interest and other information on the coalition. More news in brief.

You may also be interested in...



Portfolio Firm Glansaol Looks To Make Mark In Prestige, Led By Ex-Revlon CEO

More deals may be on the horizon for portfolio company Glansaol following its announced market entry with the acquisition of three prestige brands.

ICCR To Consider Regulatory Harmonization On Allergen Issues

At FDA’s June 2 public meeting to prepare for the eighth iteration of the International Cooperation on Cosmetics Regulation, the agency recapped accomplishments from ICCR-7 and outlined cosmetic regulatory topics to be addressed at ICCR-8. Allergens are up for discussion, as are trace materials.

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS019117

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel